Ever since our establishment in 2009, We, MiCo BioMed has been committed to improving and saving lives by offering innovative, market-leading IVD technologies. We have been overcoming countless limitations of traditional IVD devices by developing a groundbreaking “Lab-on-a-Chip” (LabChip)-based technology which enable us to deliver POCT (Point-of-care Testing) quickly and accurately. Since the outbreak of COVID-19 pandemic in 2020, we are proud to say that MiCo BioMed, with our deep expertise, dedication, and technologies, has been at the forefront of the global fight against the pandemic. As we have been actively tackling the most pressing global health threat, we also have seized many opportunities to show unprecedented growth and successfully completed our IPO on KOSDAQ. Recently we are closely keeping track of the global COVID-19 vaccination effort and continuous emergences of new COVID-19 variants. Now preparing ourselves for a post-COVID-19 era, we are evolving to be a game-changer in the global POCT market. We deeply appreciate your support for our journey.

MiCo BioMed., Ltd.
CEO Young S Hong